News

Filter

Current filters:

Vertex

1 to 9 of 49 results

Report: Global cystic fibrosis market value to treble by 2019

12-03-2014

The global cystic fibrosis market value in seven major countries will jump from $1.2 billion in 2013…

CanadaEuropeKalydecoMarkets & MarketingPharmaceuticalResearchRespiratory and PulmonaryUSAVertex

FDA backs Kalydeco for eight additional mutations that cause cystic fibrosis

22-02-2014

The US Food and Drug Administration approved biotech firm Vertex Pharmaceuticals’ supplemental New…

BiotechnologyKalydecoNorth AmericaRare diseasesRegulationUSAVertex

Vertex sells Incivo royalty rights to Janssen for $152 million

21-11-2013

Loss-making US biotech firm Vertex Pharmaceuticals says that it has sold its product royalty rights relating…

Anti-viralsBiotechnologyFinancialIncivoJanssenJohnson & JohnsonLicensingVertex

Vertex outlines progress on cystic fibrosis drug development

17-10-2013

USA-based biotech firm Vertex Pharmaceuticals provided a comprehensive update on recent progress in its…

BiotechnologyKalydecolumacaftorRare diseasesResearchVertexVX-661

Vertex reports fifth consecutive quarter of losses; updates on Kalydeco

30-07-2013

US biotech firm Vertex Pharmaceuticals (Nasdaq: VRTX) has reported second quarter revenues of $311 million,…

FinancialIncivekIncivoKalydecoNorth AmericaPharmaceuticalVertex

Vertex slumps as FDA delays hepatitis C trial

26-07-2013

US drug maker Vertex Pharmaceuticals (Nasdaq: VRTX) saw its shares drop 11% to $78 a share, in after-hours…

Anti-viralsBiotechnologyNorth AmericaPharmaceuticalRegulationResearchVertexVX-135

Vertex shoots up 60% on positive trial results for Kalydeco and VX-661

22-04-2013

US biotech firm Vertex Pharmaceuticals' (Nasdaq: VRTX) shares rocketed 60% to $84.87 Friday morning after…

BiotechnologyKalydecoRare diseasesResearchVertexVX-661

Vertex and Bristol-Myers to trial VX-135 and daclatasvir for hep C; B-MS names new R&D head

08-04-2013

US drugmaker Vertex Pharmaceuticals (Nasdaq: VRTX) has entered into a non-exclusive agreement with pharma…

Anti-viralsBristol-Myers SquibbdaclatasvirManagementPharmaceuticalResearchVertexVX-135

1 to 9 of 49 results

Back to top